Skip to content

Evaluation of the Impact of Gingivitis treatment on muscle profile

Evaluation of the Impact of Gingivitis treatment on muscle profile: a clinical-biochemical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-42b3r23
Enrollment
Unknown
Registered
2021-05-05
Start date
2021-07-16
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomatognathic diseases

Interventions

Participants will answer a questionnaire carried out by the examiner structured with questions regarding their habits (smoking, oral hygiene), general health situation (cardiovascular diseases, diabet
E06.721.189.350

Sponsors

Centro de Ensino dos Campos Gerais
Lead Sponsor
Centro de Ensino dos Campos Gerais
Collaborator

Eligibility

Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Systemically healthy patients, who do not usually perform routine physical activities, aged between 25 and 60 years, with at least 20 natural teeth with mild gingivitis at the probing depth between 4-6 mm and / or loss of clinical insertion of 3-4mm

Exclusion criteria

Exclusion criteria: Patients with some type of chronic non-communicable disease or inflammatory diseases, such as diabetes mellitus or rheumatoid arthritis, women, patients who have used antibiotics, steroids or non-steroidal anti-inflammatory drugs in the last three months and smokers will be excluded

Design outcomes

Primary

MeasureTime frame
The expected primary outcome will be the improvement in the parameters of serum creatine kinase values, an indicator of muscle profile linked to tissue damage, which is widely used. The evaluation will be carried out through blood tests, which will be used to monitor the behavior of the variation of this indicator, during the periodontal clinical treatment. The reference values indicated by the literature are 26-189 U / L (men) and 26-155 U / L (women) and will serve as a guideline for the analyzes. Although there is a range of values corresponding to normality, the indicator can vary within these limits, suggesting that the clinical treatment performed was able to act on the values.

Secondary

MeasureTime frame
No secondary outcomes are expected

Countries

Brazil

Contacts

Public ContactRodrigo Stanislawczuk Grande
rodrigozuk1@hotmail.com+55 42 3219-8000

Outcome results

None listed

Source: REBEC (via WHO ICTRP)